Poolbeg Pharma PLC CEO Share Purchase (9515B)
October 06 2022 - 2:00AM
UK Regulatory
TIDMPOLB
RNS Number : 9515B
Poolbeg Pharma PLC
06 October 2022
Poolbeg Pharma plc
CEO Share Purchase
6 October 2022 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical stage infectious disease
pharmaceutical company with a unique capital light clinical model,
has been notified that Chief Executive Officer, Jeremy Skillington,
has purchased 718,733 ordinary shares of 0.02 pence each in the
Company ("Ordinary Shares") at a share price of 4.78 pence per
share.
Following the purchase, Jeremy Skillington's beneficial interest
in the Company is 718,733 Ordinary Shares, representing 0.14 per
cent. of the total issued share capital.
Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:
"Following the significant levels of activity and excellent
progress that has been made across our growing asset portfolio over
recent months, I am pleased to now finally have the opportunity to
purchase shares in the Company. Poolbeg is entering a very exciting
phase in its development with a number of near-term value
inflection points and I am confident in our potential to create
future value for the Company and our shareholders through advancing
and partnering our pipeline of infectious disease treatments."
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 (as implemented into
English law) ("MAR").
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 20 7183 1499
finnCap Ltd (Nominated Adviser & Joint
Broker)
Geoff Nash, James Thompson, Charlie
Beeson,
Sunila de Silva (ECM), Nigel Birks +44 (0) 20 7220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 20 7496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Instinctif Partners +44 (0) 20 7457 2020
Melanie Toyne Sewell, Rozi Morris, Tim poolbeg@instinctif.com
Field
About Poolbeg Pharma
Poolbeg Pharma is a clinical stage infectious disease
pharmaceutical company, with a unique capital light clinical model
which aims to develop multiple products faster and more cost
effectively than the conventional biotech model. The Company,
headquartered in London, is led by a team with a track record of
creation and delivery of shareholder value and aspires to become a
"one-stop shop" for pharma and biotech seeking mid-stage products
to license or acquire.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025.
With its initial assets from Open Orphan plc , an industry
leading infectious disease and human challenge trials business,
Poolbeg has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg has a small molecule immunomodulator for
severe influenza (POLB 001) which has commenced its LPS human
challenge trial with initial results expected by year end 2022; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is also
developing an oral vaccine delivery platform and is progressing two
artificial intelligence (AI) programmes to accelerate the power of
its human challenge model data and biobank, with results from the
first programme expected by year end 2022.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
Notification of transactions by Directors, Persons Discharging
Managerial Responsibilities ("PDMRs") and persons closely
associated with them.
Details of the person discharging managerial responsibilities
1. / person closely associated
a) Name Jeremy Skillington
--------------------------------- -------------------------------------
Reason for the Notification
2.
------------------------------------------------------------------------
a) Position/status Chief Executive Officer
--------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
--------------------------------- -------------------------------------
Details of the issuer, emission allowance market participant,
3. auction platform, auctioneer or auction monitor
------------------------------------------------------------------------
a) Name Poolbeg Pharma plc
--------------------------------- -------------------------------------
b) LEI 213800UZ8WJLWYHBFL52
--------------------------------- -------------------------------------
Details of the transaction(s): section to be repeated for (i)
4. each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been conducted
------------------------------------------------------------------------
a) Description of the Ordinary shares of 0.02 pence each
Financial instrument,
type of instrument
--------------------------------- -------------------------------------
Identification code GB00BKPG7Z60
--------------------------------- -------------------------------------
b) Nature of the Transaction Purchase of ordinary shares
--------------------------------- -------------------------------------
c) Price(s) and volume(s) Price Volume
4.78 pence 718,733
--------
--------------------------------- -------------------------------------
d) Aggregated information As above
- Aggregated volume
- Price
--------------------------------- -------------------------------------
e) Date of the transaction 05/10/2022
--------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange
--------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDGBDGLBGDGDU
(END) Dow Jones Newswires
October 06, 2022 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Poolbeg Pharma (LSE:POLB)
Historical Stock Chart
From Jul 2023 to Jul 2024